Baxevanis C N, Reclos G J, Papamichail M, Tsokos G C
Department of Immunology, Hellenic Anticancer Institute, Athens, Greece.
Immunopharmacol Immunotoxicol. 1987;9(4):429-40. doi: 10.3109/08923978709035224.
Systemic lupus erythematosus (SLE) is characterized by a variety of profound T-cell abnormalities among which are decreased autologous and allogeneic mixed lymphocyte reactions (auto-MLR and allo-MLR, respectively). In a group of 10 patients with SLE, the mean auto-MLR and allo-MLR responses, tested by tritiated thymidine incorporation, were significantly decreased. If optimal doses of highly purified prothymosin alpha (ProT alpha) were present during the auto- of allo-MLR, the T-cell proliferative responses of SLE patients were increased to normal levels. ProT alpha had more pronounced enhancing effect in patients than in normal individuals. Among patients, ProT alpha was more effective in those who had active disease and low proliferative responses. These results demonstrate that ProT alpha can fully restore the deficient T-cell proliferative responses in auto- and allo-MLR in patients with SLE. ProT alpha, or a certain peptidic fragment of it, could prove potentially useful in the treatment of SLE.
系统性红斑狼疮（SLE）的特征是多种严重的T细胞异常，其中包括自体和异体混合淋巴细胞反应（分别为自身混合淋巴细胞反应和异体混合淋巴细胞反应）降低。在一组10例SLE患者中，通过氚标记胸腺嘧啶核苷掺入法检测的平均自身混合淋巴细胞反应和异体混合淋巴细胞反应显著降低。如果在自身或异体混合淋巴细胞反应过程中存在最佳剂量的高度纯化的前胸腺素α（ProTα），SLE患者的T细胞增殖反应会增加到正常水平。ProTα在患者中的增强作用比在正常个体中更明显。在患者中，ProTα对那些患有活动性疾病且增殖反应低的患者更有效。这些结果表明，ProTα可以完全恢复SLE患者自身和异体混合淋巴细胞反应中缺陷的T细胞增殖反应。ProTα或其特定的肽片段可能在SLE的治疗中证明具有潜在用途。
